Anixa Biosciences (ANIX) 10-Q2024 Q3 Quarterly report

Filed: 6 Sep 24, 5:00pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: anecdotal, case, contemplated, detailed, encouraging, exhibiting, fully, Immunotherapy, Jul, key, permission, Qualitative, Quantitative, reduction, SCHEDULE, single, SITC, Society, sought, tumor, varying

Removed: acceptable, assurance, capital, competitive, complementary, continue, fail, failure, favorable, force, generate, hand, harm, highest, highly, historically, inhibit, insufficient, invest, lack, limiting, liquid, mature, obtain, preventative, private, reinvested, reinvestment, respond, return, satisfy, security, seek, sustain, synergistic, unanticipated

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ANIX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Statement of Chief Executive Officer

Pursuant to Section 1350 of Title 18 of the United States Code

Pursuant to Section 1350 of Title 18 of the United States Code, the undersigned, Dr. Amit Kumar, the Chairman and Chief Executive Officer of Anixa Biosciences, Inc., hereby certifies that:

	1.	The Company’s Form 10-Q Quarterly Report for the period ended July 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	By:	/s/ Dr. Amit Kumar
		Dr. Amit Kumar
		Chairman and Chief Executive Officer
September 6, 2024		(Principal Executive Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.